The Josep Carreras Institute is part of the Cancer Proteome project, an international initiative to study malignant tumors. He has the support of the Spanish Ministry of Science and Innovation, whose Minister Diana Morant visited the Josep Carreras Institute on Thursday and announced a 1m-euro grant to promote the project.
The Josep Carreras Leukemia Research Institute, led by Dr. Manel Esteler and supported by the Spanish Ministry of Science and Innovation, joins the Cancer Proteome project, a program to promote a line of research on protein characterization in malignancies that will allow us to learn more about the causes of leukemia.
On the occasion of the Josep Carreras Institute’s entry into the cancer proteome project, Spanish Science and Innovation Minister Diana Morant visited the research center on Thursday and announced that the ministry would allocate one million euros to promote the initiative. During his visit, Minister Morant was accompanied by Albert Carreras and Cole and Albert Carreras Perez, representing the Carreras family, the director of the institute, Dr. Manel Esteler; the chairman of the institution’s delegate committee, Dr. Evarist Feliu, and the acting director of the institute, Anna Garrido. Badalona Mayor Ruben Guigaró also attended the event.
Much effort has been made over the last twenty years to identify the cancer genome. Decoding the genetic changes of human tumors is largely possible thanks to the Cancer Genome Atlas (TCGA), run by the National Cancer Institute (NCI) in the United States, which sequences the DNA of more than 500 tumor samples extracted from each tissue and organ in the body.
However, one key point in the study of the cellular and molecular cause of cancer was still missing: the characteristic of the protein, the product produced by our genetic material. In this regard, the NCI recently launched the International Proteogenomic Consortium (ICPC) program to obtain a profile of all altered proteins in all human tumors, the so-called “Proteome”. The Josep Carreras Research Institute for Leukemia (IJC), led by Dr. Manel Esteler and with the support of the Spanish Ministry of Science and Innovation, has officially joined the consortium to discover the leukemia proteome.
One in five cancers comes from blood or lymph nodes. Our work in this international program will be to uncover the proteome of leukemia, especially the so-called B-cell acute lymphoblastic leukemia (B-ALL). We will examine in detail the altered expression and modification of the protein in this disease in both adults and the pediatric population, as well as their implications for the clinical management of these patients and the discovery of new treatments against the discovered altered targets.
Dr. Manel Esteler, research coordinator
Dr Henry Rodriguez, founder of the Office for Clinical Research on Cancer Proteomics at the National Cancer Institute and a member of President Joe Biden’s Advisory Council on Cancer Research, said: “It is a great pleasure to acknowledge Josep Carreras’ research work institute. I am convinced that their abnormal characterization of proteins in leukemia, combined with data on changes throughout the genome, will be a major breakthrough in personalized cancer medicine that will improve the quality of life and survival of patients.